|Videos|November 26, 2013
Episode 3 - Radium-223 for the Treatment of CRPC
Advertisement
Episodes in this series
In addition to cytotoxic chemotherapy, immunotherapy, and oral agents that target the androgen pathway, David Crawford, MD, discusses radium-223 as a therapeutic option for the treatment of castration-resistant prostate cancer (CRPC).
Dr Crawford cites the ALSYMPCA clinical trial and explains how the trial tested radium-223 and found that the drug demonstrated several benefits to patients with CRPC. Benefits included increased survival rates, decreased instances of overall pain, and lower numbers of symptomatic skeletal events and fractures, as well as lessened the need for treatment with surgery or radiation.
Advertisement
Related to this article
Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable obesity care infrastructure.
The study authors note there is an urgent need for "innovative value-based and alternative payment models of care."
A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.
Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.
Older adults on Medicare report the best access to care among 10 countries but more cost-related problems and higher out-of-pocket spending.
The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
The trade group says CMS lacks authority to impose GLOBE, which is set to begin January 1.
Advertisement
Advertisement
Trending on AJMC
1
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
2
NEI Director Highlights Pediatric Advances, AI’s Promise in Eye Care
3
GLP-1s Have Protective Benefit Against DME, Glaucoma Surgery
4
Keynote Address Tackles AI’s Role in Health Care, Eye Care
5